Haha yes Lexcorp, progress may seem slow and another capital...

Haha yes Lexcorp, progress may seem slow and another capital raise is on the horizon, it's all about perspective.

Is the glass half empty, or is it half full?

In the context of OncoSil, a capital raise could be seen as an opportunity to fund pivotal initiatives that could fundamentally change the company's trajectory.

Upcoming milestones like GBA and FDA discussions aren't just checkboxes; they're potential game-changers that could revitalize investor interest and financial stability.

A 'snail's pace' in the biotech sector isn't uncommon, but when breakthroughs happen, they can happen fast and have a significant impact.

Yep, your caution is warranted, so is optimism.